| Today's Big NewsNov 16, 2022 |
| By James Waldron Novartis has halted a phase 1 trial of its CD73 antagonist due to a low likelihood of efficacy, although the Big Pharma will continue to explore the therapy’s potential as part of a combo regimen. |
|
|
|
By Nick Paul Taylor NextCure has found a new use for its anti-B7-H4 antibody NC762. By partnering with Korea’s LegoChem Biosciences, the biotech plans to aim an antibody-drug conjugate at the oncology target and join an R&D race featuring AstraZeneca, Mersana Therapeutics and Seagen. |
By Max Bayer Gene therapy biotech Kriya Therapeutics is continuing its acquisition streak to build out a pipeline, this time with a focus on the brain. The North Carolina-based biotech is buying Redpin Therapeutics to expand, acquiring treatments for epilepsy and trigeminal neuralgia. There were no dollar figures included in Wednesday’s deal announcement and a press contact for Kriya said financial details weren’t being disclosed. |
Sponsored by Phreesia Life Sciences While the industry has yet to address a big barrier to trial enrollment—low patient knowledge—the good news is that patients want to learn more, according to survey data from Phreesia Life Sciences. |
By Nick Paul Taylor CureVac is rethinking development of immunity activator CV8102 in the wake of the publication of data from a checkpoint inhibitor combination trial, vowing to only consider further clinical studies if the drug candidate is paired with “a defined mRNA cancer vaccine.” |
Sponsored by ThermoFisher Scientific Every mRNA manufacturing process step adds complexity and cost, so it’s important to ensure steps are compatible and integrated with each other. Explore each intertwined step in this infographic. |
By Gabrielle Masson Rafael Holdings is laying off staff and giving up on early-stage R&D efforts that were touted as the company’s main focus less than a year ago, as it pivots to seeking out investment, acquisition or in-licensing opportunities. |
By Helen Floersh Scientists have identified an enzyme that, when inhibited, could curtail the spread of medulloblastoma and limit the need for chemo and radiation. |
By Conor Hale Illumina has begun to lay off about 5% of its global workforce spanning more than 9,100 people, a move the DNA sequencing giant described as “proactively realigning” its core operations in the face of broader macroeconomic difficulties. |
By Kevin Dunleavy Five key COVID-19 drugs including Merck’s antiviral Lagevrio and AstraZeneca’s Evusheld could be rejected for government funding in the U.K. In draft guidance, the drug cost watchdog the National Institute for Health and Care Excellence (NICE), recommended against government coverage because of concerns about either their cost or effectiveness. Gilead’s Veklury, Regeneron’s Ronapreve and GSK-Vir Biotechnology’s Xevudy also made their list. |
By Heather Landi LAS VEGAS—Google Cloud and Epic, one of the largest medical records software companies in the U.S., inked a deal to enable hospital customers to run their Epic workloads on the tech giant's cloud technology. |
By Andrea Park For the second time this year, Pear Therapeutics is laying off employees to cut costs and extend its cash runway through 2023. |
By Frank Diamond Thousands of youngsters were rushed to emergency departments because of suicidal ideation. The problem, bad before the pandemic, appears to be getting worse. |
Fierce podcastsDon't miss an episode |
| | This week on “The Top Line,” we share some highlights from Fierce Biotech's Cell and Gene Therapy Forum in case you missed it. |
|
|---|
|
|
|
Tuesday, December 6, 2022 | 10am ET / 7am PT The development of therapeutic antibodies has been challenged by the difficulty to generate such intricate molecules. Here, we show that ProBio has established proprietary fast CMC platform guaranteeing the delivery of monoclonal antibody with high titer. Register now.
|
|
| Whitepaper Learn how to develop a high-performing supply chain for GMP-manufactured chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific. Sponsored by: Thermo Fisher Scientific |
| WhitepaperPreparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
| Webinar Twist Bioscience CSO Dr. Aaron Sato shares how Twist's tools for antibody discovery have been applied to identify antibodies against diverse and challenging targets. See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Presented by: Twist Bioscience |
| WhitepaperRead through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL |
| WhitepaperThis paper outlines how gene therapy supply chains are different from traditional biopharma products, as well as the factors that are essential to success. Sponsored by: Blue Matter |
| VideoRevolutionize your monoclonal antibody (mAb) manufacturing process with the Gibco™️ Efficient-Pro™️ Medium and Feed System. Watch our how-to video. Sponsored by: Thermo Fisher Scientific |
| WhitepaperWhat is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
| ResearchLearn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
| WhitepaperHow can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
| WhitepaperLearn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
| WebinarYpsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
| WhitepaperClarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
| WhitepaperLearn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
| eBookOrally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored By: Catalent |
| WhitepaperDid you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored By: Catalent |
| WhitepaperWhat are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| |
|
